Showing 5141-5150 of 5162 results for "".
DermWireTV: Qwo Approved, Assessing Resident Anxiety
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-qwo-approved-assessing-resident-anxiety/19830/FDA has approved Qwo (collagenase clostridium histolyticum-aaes) from Endo, the first injectable treatment approved for moderate to severe cellulite in the buttocks of adult women. A recent survey offers perspective on anxiety among third-year dermatology residents in light of the COVID crisis. AlleDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyDermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinDermWireTV: Medicare Cuts; Revision, Alastin, Obagi Acquisitions; CSF Hits Nashville
https://practicaldermatology.com/topics/practice-management/dermwiretv-medicare-cuts-revision-alastin-obagi-acquisitions-csf-hits-nashville/20033/Congress is working to avert a potential pay cut for physicians who treat Medicare patients, and a bipartisan solution has been introduced. Cuts loom as the AMA has released data showing that Medicare claims data exclusive to physician services fell an estimated $13.9 billion or 14 percent below expBryhali, Xepi Launches; Epionce's New Facility
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-bryhali-xepi-launches-epionce-s-new-facility/18213/Bryhali (halobetasol propionate) 0.01% Lotion from Ortho Dermatologics is now available for the topical treatment of plaque psoriasis in adults. Lawrence J. Green, MD a lead investigator on the Phase 3 studies speaks to DermWireTV. Botanical-based skincare company Epionce has a new 18,500 square fooDr. Joel Schlessinger discusses the use of credit cards in his practice
https://practicaldermatology.com/topics/practice-management/dr-joel-schlessinger-discusses-the-use-of-credit-cards-in-his-practice/19123/To create the most convenient experience for patients, dermatologist's offices must have the ability to process credit cards. When you incorporate this practice into your clinic or spa, it is important to understand all aspects of the transaction. In this video, Dr. Joel Schlessinger offers advice oUsing Dermoscopy For Improved Clinical Decisions
https://practicaldermatology.com/conferences/maui-derm-2024/using-dermoscopy-for-improved-clinical-decisions/20264/Resident Of Distinction Award-winner Chloe Fernandez, DO, PGY-2 resident at the ADCS Orlando Dermatology Program, reviews a presentation on dermoscopy in special sites such as the palms, soles, and face, and talks about its importance to both her personal training as well as the benefits for patientGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dDermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For thDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)